Immunotherapy with Long-Lived Anti-CD20 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias

被引：0
|
作者：
Chu, Seung Y. [1 ]
Lee, Sung-Hyung [1 ]
Rashid, Rumana [1 ]
Chen, Hsing [1 ]
Chan, Emily W. [1 ]
Phung, Sheryl [1 ]
Pong, Erik [1 ]
Endo, Nancy A. [1 ]
Miranda, Yvonne [1 ]
Bonzon, Christine [1 ]
Leung, Irene W. L. [1 ]
Muchhal, Umesh S. [1 ]
Moore, Gregory L. [1 ]
Bernett, Matthew J. [1 ]
Szymkowski, David E. [1 ]
Desjarlais, John R. [1 ]
机构：
[1] Xencor Inc, Monrovia, CA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] BISPECIFIC ANTIIDIOTYPE ANTI-CD3 ANTIBODY THERAPY OF MURINE B-CELL LYMPHOMA
    WEINER, GJ
    HILLSTROM, JR
    JOURNAL OF IMMUNOLOGY, 1991, 147 (11): : 4035 - 4044
  • [22] Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 x Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma
    Moore, Gregory L.
    Lee, Sung-Hyung
    Schubbert, Suzanne
    Miranda, Yvonne
    Rashid, Rumana
    Pong, Erik
    Phung, Sheryl
    Chan, Emily W.
    Chen, Hsing
    Endo, Nancy
    Ardila, Maria C.
    Bernett, Matthew J.
    Chu, Seung
    Leung, Irene W. L.
    Muchhal, Umesh
    Bonzon, Christine
    Szymkowski, David E.
    Desjarlais, John
    BLOOD, 2015, 126 (23)
  • [23] The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer
    Zhao, Huijun
    Ma, Juan
    Lei, Ting
    Ma, Wanru
    Zhang, Man
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 810 - 817
  • [24] Immunotherapy with FBTA05 (Bi20), a trifunctional anti-CD3 x anti-CD20 antibody in recurrent childhood B-cell malignancies
    Schuster, F.
    Stanglmaier, M.
    Woessmann, W.
    Winkler, B.
    Meisel, R.
    Schlegel, P. G.
    Lindhofer, H.
    Reiter, A.
    Borkhardt, A.
    Buhmann, R.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S247 - S247
  • [25] Targeting CD20+ Rituxan resistant B-cells with anti-CD3 activated T cells (ATC) armed with anti-CD3 x anti-CD20 (CD20Bi)
    Gall, JM
    Grabert, RC
    Deavers, M
    Davoll, PA
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 2004, 32 (07) : 35 - 35
  • [26] Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
    Funakoshi, S
    Longo, DL
    Murphy, WJ
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02): : 93 - 101
  • [27] Therapeutic effects of the anti-CD74 mAb, milatuzumab, compared to anti-CD20 antibodies, in B-cell lymphomas
    Stein, Rhona
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3353S - 3354S
  • [28] Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
    Gupta, Pankaj
    Goldenberg, David M.
    Rossi, Edmund A.
    Cardillo, Thomas M.
    Byrd, John C.
    Muthusamy, Natarajan
    Furman, Richard R.
    Chang, Chien-Hsing
    BLOOD, 2012, 119 (16) : 3767 - 3778
  • [29] T cell-dependent bispecific antibody anti-CD79b/CD3 as a potential therapy for B-cell malignancies
    Wang, Peiyin
    Hristopoulos, Maria
    Clark, Robyn
    Chen, Yvonne
    Ellerman, Diego
    Mathieu, Mary
    Spiess, Christoph
    Li, Jessica
    Chalouni, Cecile
    Sukumaran, Siddharth
    Stefanich, Eric
    Wallin, Jeffrey
    Li, Robert
    Zabka, Tanja
    Totpal, Klara
    Dennis, Mark
    Ebens, Allen
    Gould, Stephen
    Polson, Andrew
    Sun, Liping Laura
    CANCER RESEARCH, 2017, 77
  • [30] TREATMENT OF MURINE B-CELL LYMPHOMA WITH BISPECIFIC MONOCLONAL-ANTIBODIES (ANTIIDIOTYPE X ANTI-CD3)
    DEMANET, C
    BRISSINCK, J
    VANMECHELEN, M
    LEO, O
    THIELEMANS, K
    JOURNAL OF IMMUNOLOGY, 1991, 147 (03): : 1091 - 1097
12345